UK markets closed

Burning Rock Biotech Limited (6BU0.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
2.42000.0000 (0.00%)
As of 03:29PM CEST. Market open.
Full screen
Previous close2.4200
Open2.4200
Bid5.7000 x N/A
Ask6.3500 x N/A
Day's range2.4200 - 2.4200
52-week range2.4200 - 22.2000
VolumeN/A
Avg. volume0
Market cap61.958M
Beta (5Y monthly)0.18
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement

    GUANGZHOU, China, June 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it has received a notification letter from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“NASDAQ”) on May 30, 2024, informing the Company that it has regained compliance with the m

  • GlobeNewswire

    Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines

    GUANGZHOU, China, May 30, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) has recently announced a collaboration with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx), aiming to provide diagnostic methods, to enable treatment choice for patients with cancer in China, while driving innovation and development in cancer therapy. This collaboration will focus on the development of companion dia

  • GlobeNewswire

    Burning Rock Reports First Quarter 2024 Financial Results

    GUANGZHOU, China, May 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2024. Recent Business Updates Early Detection THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Editi